Skip to Main Content

A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH (VOYAGE)

Conditions

Diseases of the Digestive System - Liver

Phase II

What is the purpose of this trial?

To evaluate the effects of VK2809 compared to placebo on liver fat content (assessed by MRI-PDFF, Magnetic Resonance Imaging- Proton Density Fat Fraction).

The study includes 52 weeks, double-blind treatment period. Clinic visits will occur at Randomization and every four weeks from Week 4 through Week 52 and through End of Study period. The study includes a post-dosing study visit that will occur 4 weeks after the last dose of study drug. This visit represents the End-of-Study Visit (Week 56 Visit). Three hundred thirty-seven subjects will be enrolled into five treatment arms and there will be an equal distribution of males and females in each treatment arm. Subjects will be stratified by gender, fibrosis stage, and diabetes status.

  • Trial with
    Viking Therapeutics, Inc.
  • Start Date
    07/19/2021
  • End Date
    03/31/2021

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    07/26/2021
  • Study HIC
    #2000029514